EasyCookieInfo

Rome, April 9, 2019 - Takis S.r.l. (“TAKIS”) and Trianni, Inc. ("TRIANNI") today announced Takis access to the Trianni mice platform as service provider.

TAKIS is proud to announce that the Company can now offer antibody generation services to using the Trianni Mouse™. TRIANNI is a biotech company specialized in antibody discovery technology and TAKIS is now able to provide fully human monoclonal antibodies for Clients that hold a license for the use of the Trianni mouse.

TRIANNI’s lead technology, The Trianni Mouse™ enables efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.

Dr Giuseppe Roscilli, Director of the Antibody Department at Takis, stated: “Takis has a thorough experience in the development of custom monoclonal antibodies and the Trianni Mouse integration with our antibody generation technologies, especially with in vivo electro-gene-transfer of plasmid DNA (DNA-EGT) vaccination system, allows to provide our worldwide customers with an efficient platform for the discovery and development of fully human antibodies”.

Dr. Luigi Aurisicchio, CEO of Takis, stated: "We are happy to be chosen by Trianni for antibody discovery services. With the aim to offer best-in-class services to our Clients, Takis has been looking for technologies that would allow the efficient generation of humanized antibody. The Trianni Mouse is a unique platform to develop fully human monoclonal antibodies and it is now an integral component of our service portfolio."

"We are pleased to have Takis provide services using the Trianni mouse" stated Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This collaboration allows Customers that have a license for the Trianni platform to access the Takis expertise and vaccination technologies”.

 

About Takis S.r.l.
Takis is a privately held organization, founded in 2009 by former Merck Research Laboratories employees. The group has more than 15 years of experience and an established track record in drug discovery in Oncology and is recognized for the conception and implementation of a number of innovative technologies. One of the main assets of Takis is the expertise in in vivo Electro-Gene-Transfer (DNA-EGT), which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy to antibody development. Takis pipeline include four Cancer Vaccine candidates based on this technology. Takis is actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases. Takis operates worldwide as a Contract Research Organization providing the highest quality and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery. Takis has established multiple service and discovery agreements with Biotech and Pharma partners, among them Alfasigma and Italfarmaco in Oncology and inflammatory diseases, Incyte and Boehringer Ingelheim for Immune-Oncology, Johnson & Johnson’s for Immunology, Glaxo-Smith-Kline for Antibody generation. For additional information please go to www.takisbiotech.it.


About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.

 

Contacts- TAKIS
Giuseppe Roscilli, PhD
Director, Monoclonal Antibody Department
+39.0650576077
This email address is being protected from spambots. You need JavaScript enabled to view it.


Contacts- TRIANNI
Mandy Boyd
Director of Marketing
TRIANNI
1.415.231.0256 [o]
1.866.674.9314
This email address is being protected from spambots. You need JavaScript enabled to view it.


SOURCE Takis S.r.l. (www.takisbiotech.it)

Download PDF

This week "Il Corriere della Sera" published an article in the Biotechnology section describing our product Rever3mAb. This is a monoclonal antibody able to “revert” resistance to conventional anticancer therapies.

Research on biological drugs is expected to revolutionize cancer treatment: we are working hard to bring Rever3mab to clinical practice, in order to really make a change in the life of patients. 

The article also mentions VITARES and our committment to raise people’s awareness of the importance of scientific and translational research for the implementation of effective anticancer therapies.

We are proud to coordinate this amazing project!

For more information: Progetto: REVER3MAB - UE, Stato e Regione

 

 

Luigi Aurisicchio, CEO/CSO at Takis, has been interviewed at Radio Roma Capitale – Live Social. He told the listeners about the story of Takis, Evvivax and VITARES, all born in the amazing technological center at Castel Romano, near Rome, where high-level research and innovation are constantly pursued in a highly stimulating scientific environment.  

He summarized Takis research for the generation of anticancer vaccines, immunological treatments and new drugs against rare diseases. He also described our commitment to create networks of collaboration between Human and Veterinary Medicine for Translational Research.

Listen to the interview (in Italian): LiveSocial

Takis is proud to announce the publication of the article "The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?" by Di Mambro et al on Frontiers in Pharmacology.

Fungal infections are deadly diseases in immunocompromised hosts. Most importantly, fungi are becoming resistant to current treatments. Here, we summarize currently used antifungal agents and propose novel therapeutic approaches, including new fungal molecular targets to be considered for drug development.

Takis has an active program on the generation of monoclonal antibodies against Aspergillus Fumigatus and other species. We set up a rodent model of Invasive Aspergillosis, which is suitable for the evaluation of new drugs and combination with existing standard of care.

Full article available at: The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?

Takis is glad to sponsor the first Vitares Annual Congress, which is also the first Italian One Health meeting focusing on Cancer Immunotherapy.

This meeting brings together Basic research, Veterinary and Human Medicine Scientists involved in the field of Immunology, Oncology and Education, aiming at creating networks of collaboration. Internationally renowned scientists from Italy and abroad will provide the State of the Art and present their most recent data in a highly stimulating scientific environment.

Public health initiatives such as One Health demonstrate the growing awareness of the fact that animal and human health are strongly interconnected with each other and with the environment. Zoonotic pathogens and Cancer represent a direct hazard to Veterinary and Human Health”, said Luigi Aurisicchio, CEO/CSO at Takis and president at Vitares.

Looking forward to meeting you in Rome!

 

 

We are proud to announce the first POC data achieved in advanced preclinical models with our personalized vaccine platform based on NeoAntigen Identification/DNA Electroporation and published on Journal of Experimental & Clinical Cancer Research.

 

We have developed different neoantigen minigene vaccine vectors to determine the rules for a successful neoantigen cancer vaccine delivered by plasmid DNA and electroporation. We found that a strong poly-functional and poly-specific immune response was observed with high affinity neoantigens. Our pipeline - from the selection of neoantigens to vaccine design – was also applied to a new model of patient derived tumor xenograft resulting in therapeutic treatment.

These results suggest a feasible strategy for a neoantigen cancer vaccine that is simple and applicable for clinical developments.

Read the full article: https://doi.org/10.1186/s13046-019-1084-4